Financial Performance - Revenue for the six months ended June 30, 2024, increased to RMB 93.71 million, representing a growth of 13.6% compared to RMB 82.50 million for the same period in 2023[2]. - The loss before tax for the six months ended June 30, 2024, was RMB 82.73 million, compared to RMB 40.53 million for the same period in 2023[2]. - The basic and diluted loss per share for the six months ended June 30, 2024, was RMB (0.79), compared to RMB (0.36) for the same period in 2023[2]. - The company reported a net loss of RMB 81,488 thousand for the six months ended June 30, 2024, compared to a net loss of RMB 41,017 thousand in 2023, reflecting a deterioration in financial performance[67]. - Gross profit for the same period was RMB 53,756 thousand, compared to RMB 51,364 thousand in 2023, indicating a slight increase in profitability[66]. - The group reported a pre-tax loss of RMB 39,954,000 for the six months ended June 30, 2024, compared to RMB 31,138,000 for the same period in 2023, representing a 28.4% increase in losses[76]. Revenue Growth - Total revenue increased by 13.6% from RMB 82.5 million for the six months ended June 30, 2023, to RMB 93.7 million for the six months ended June 30, 2024, driven by a 22.1% growth in Eagle Eye Medical and a 22.7% increase in Eagle Eye Health[30]. - Revenue from customer contracts for the six months ended June 30, 2024, was RMB 93,710,000, an increase of 13.4% from RMB 82,502,000 for the same period in 2023[74]. - Revenue from medical institutions (Eagle Eye Medical) was RMB 36,450,000, up from RMB 29,845,000, representing a growth of 22.3%[74]. - Revenue from Eagle Eye Health reached RMB 38.0 million during the reporting period, contributing to the overall growth of the company's eye health business[26]. Asset Management - Non-current assets increased to RMB 529.75 million as of June 30, 2024, compared to RMB 402.99 million as of December 31, 2023[2]. - Current assets decreased to RMB 1,017.62 million as of June 30, 2024, from RMB 1,281.93 million as of December 31, 2023[2]. - Property, plant, and equipment increased from RMB 180 million to RMB 202 million, driven by the expansion of hardware for market growth[41]. - Inventory decreased from RMB 401 million to RMB 282 million, reflecting effective inventory management[42]. - Cash and cash equivalents decreased from RMB 8,915 million to RMB 5,478 million, mainly due to purchases of financial assets[47]. Research and Development - The company continues to enhance its R&D capabilities in myopia prevention, positioning itself with a competitive advantage in the market[6]. - Research and development expenses decreased by 13.3% from RMB 565 million to RMB 490 million, attributed to streamlined R&D processes[35]. - The company has published over 20 papers in prestigious scientific journals and conferences, demonstrating the high performance of its products[17]. - The company has obtained 20 new patents during the reporting period, bringing the total to 258 patents, including 122 inventions[18]. Market Expansion - The company aims to expand its presence in overseas markets, including Malaysia, Singapore, Thailand, UAE, and South Africa, with expected gradual increases in sales from these new markets[28]. - Overseas revenue amounted to RMB 4.6 million, accounting for 4.9% of total revenue during the reporting period, reflecting progress in international market expansion[24]. - The company has deployed its AI solutions in over 296 health check centers, with some centers achieving a repurchase rate of over 50%[21]. Product Development - The company has developed a comprehensive AI product matrix for retinal diagnosis and treatment, including AI for retinal imaging, myopia prevention, and visual training[6]. - The AI retinal imaging recognition product has received approval as the first Class III AI diagnostic product from the National Medical Products Administration in China[16]. - The company’s core product, Airdoc-AIFUNDUS, is a leading AI software as a medical device (SaMD) for assisting in diabetic retinopathy diagnosis, with multiple versions in development[10]. - The AI-FUNDUSCAMERA series aims to address existing pain points in retinal imaging while reducing costs through AI-driven technology[12]. Employee and Operational Management - Total employee compensation for the six months ended June 30, 2024, amounted to RMB 102.9 million[61]. - The company has 254 full-time employees as of June 30, 2024[61]. - The company has adopted a share incentive plan to motivate employees as of January 13, 2023[61]. - The group recognized a total employee benefit expense of RMB 102,861,000 for the six months ended June 30, 2024, compared to RMB 98,053,000 in 2023, representing a 4.5% increase[76]. Compliance and Risk Management - The company has maintained compliance with relevant laws and regulations in its operations in China and Hong Kong[57]. - The company has implemented foreign exchange risk monitoring policies to address potential currency risks[60]. - The group emphasizes strict management measures to ensure the safety and effectiveness of its medical devices[92].
鹰瞳科技-B(02251) - 2024 - 中期业绩